Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia ; volume:9 ; number:1 ; day:13 ; month:5 ; year:2021 ; pages:1-6 ; date:12.2021
Biomarker Research ; 9, Heft 1 (13.5.2021), 1-6, 12.2021
- Creator
-
Mistry, Jayna J.
Hellmich, Charlotte
Lambert, Amelia
Moore, Jamie A.
Jibril, Aisha
Collins, Angela
Bowles, Kristian M.
Rushworth, Stuart A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-021-00291-y
- URN
-
urn:nbn:de:101:1-2021091321360658241607
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mistry, Jayna J.
- Hellmich, Charlotte
- Lambert, Amelia
- Moore, Jamie A.
- Jibril, Aisha
- Collins, Angela
- Bowles, Kristian M.
- Rushworth, Stuart A.
- SpringerLink (Online service)
Other Objects (12)
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia